One Pass Tirofiban In Management of Ischemic Stroke Thrombectomy In China
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.
Also called NCT04851457
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT04851457
-
- Other papers using this trial's data
- Tirofiban on First-Pass Recanalization in Acute Stroke Endovascular Thrombectomy: The OPTIMISTIC Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04851457. Randomized; single masking; primary purpose treatment. Start 2021-04-06 (actual); primary completion 2023-07-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- One Pass Tirofiban In Management of Ischemic Stroke Thrombectomy In China
- Acronym
- OPTIMISTIC
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Intravenous tirofiban combination therapy
- Lead sponsor
- Shanghai East Hospital
- Collaborator
- Shanghai 6th People's Hospital
- Collaborator
- Ningbo No. 1 Hospital
- Collaborator
- Zhangzhou Municipal Hospital of Fujian Province
- Collaborator
- Shanghai 7th People's Hospital
- Collaborator
- Jinan Central Hospital
- Collaborator
- Xuchang Central Hospital
Record details
- Record id
cardio:ct-nct04851457- Content hash
3180d46ca63706c194c45e5bf1a846a204931e6a7b78cd7874b71cfbd048ec34